Opioid and gabapentinoid prescriptions in England from 2015 to 2020
<h4>Purpose</h4> Concerns gradually arose about misuse of gabapentinoids (gabapentin and pregabalin), especially when used in combination with opioids. Because it can be a driver of usage, trends in prescribing habits may be interesting to analyse. The aim of this study is to examine the...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9704625/?tool=EBI |
| _version_ | 1811315697622450176 |
|---|---|
| author | Yixue Xia Patrice Forget |
| author_facet | Yixue Xia Patrice Forget |
| author_sort | Yixue Xia |
| collection | DOAJ |
| description | <h4>Purpose</h4> Concerns gradually arose about misuse of gabapentinoids (gabapentin and pregabalin), especially when used in combination with opioids. Because it can be a driver of usage, trends in prescribing habits may be interesting to analyse. The aim of this study is to examine the evolution of prescriptions of opioids and gabapentinoids in England from 2015 to 2020 at a regional level. <h4>Methods</h4> This study included data from April 2015 to February 2020, focusing on prescribing data, extracted the OpenPrescribing database. We described the evolution of the prescriptions of opioids and gabapentinoids and calculated their ratios for each month. We used Analyses of Variance (ANOVAs) to compare data between and within regions (over time). <h4>Results</h4> During this period, opioid prescriptions remained stable (from -3.3% to +2.2%/year) and increased for gabapentinoids generally (from +1.5% to +2.2%). The ratio between gabapentinoid to opioid prescriptions increased by more than 20% in 2020 compared to 2015, variably between regions (F(6,406) = [120.2]; P<0.001; LSD Test: P<0.001; ANOVA for repeated measures: P<0.05). In 2019, a decline in the ratio occurred in all regions, but only persisting in the London commissioning region in 2020 (-14.4% in comparison with 2018, 95%CI: -12.8 to -16.3). <h4>Conclusions</h4> Gabapentinoids are increasingly prescribed in England. The ratio of gabapentinoid to opioid prescriptions in England increased from 2015 to 2020. The reclassification of gabapentinoids as controlled drugs, in 2019, may have been associated with a significant reduction, although larger prescribers may have been less influenced. |
| first_indexed | 2024-04-13T11:34:48Z |
| format | Article |
| id | doaj.art-1592ffe28a9d40f092c9520b15f5164a |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-13T11:34:48Z |
| publishDate | 2022-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-1592ffe28a9d40f092c9520b15f5164a2022-12-22T02:48:28ZengPublic Library of Science (PLoS)PLoS ONE1932-62032022-01-011711Opioid and gabapentinoid prescriptions in England from 2015 to 2020Yixue XiaPatrice Forget<h4>Purpose</h4> Concerns gradually arose about misuse of gabapentinoids (gabapentin and pregabalin), especially when used in combination with opioids. Because it can be a driver of usage, trends in prescribing habits may be interesting to analyse. The aim of this study is to examine the evolution of prescriptions of opioids and gabapentinoids in England from 2015 to 2020 at a regional level. <h4>Methods</h4> This study included data from April 2015 to February 2020, focusing on prescribing data, extracted the OpenPrescribing database. We described the evolution of the prescriptions of opioids and gabapentinoids and calculated their ratios for each month. We used Analyses of Variance (ANOVAs) to compare data between and within regions (over time). <h4>Results</h4> During this period, opioid prescriptions remained stable (from -3.3% to +2.2%/year) and increased for gabapentinoids generally (from +1.5% to +2.2%). The ratio between gabapentinoid to opioid prescriptions increased by more than 20% in 2020 compared to 2015, variably between regions (F(6,406) = [120.2]; P<0.001; LSD Test: P<0.001; ANOVA for repeated measures: P<0.05). In 2019, a decline in the ratio occurred in all regions, but only persisting in the London commissioning region in 2020 (-14.4% in comparison with 2018, 95%CI: -12.8 to -16.3). <h4>Conclusions</h4> Gabapentinoids are increasingly prescribed in England. The ratio of gabapentinoid to opioid prescriptions in England increased from 2015 to 2020. The reclassification of gabapentinoids as controlled drugs, in 2019, may have been associated with a significant reduction, although larger prescribers may have been less influenced.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9704625/?tool=EBI |
| spellingShingle | Yixue Xia Patrice Forget Opioid and gabapentinoid prescriptions in England from 2015 to 2020 PLoS ONE |
| title | Opioid and gabapentinoid prescriptions in England from 2015 to 2020 |
| title_full | Opioid and gabapentinoid prescriptions in England from 2015 to 2020 |
| title_fullStr | Opioid and gabapentinoid prescriptions in England from 2015 to 2020 |
| title_full_unstemmed | Opioid and gabapentinoid prescriptions in England from 2015 to 2020 |
| title_short | Opioid and gabapentinoid prescriptions in England from 2015 to 2020 |
| title_sort | opioid and gabapentinoid prescriptions in england from 2015 to 2020 |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9704625/?tool=EBI |
| work_keys_str_mv | AT yixuexia opioidandgabapentinoidprescriptionsinenglandfrom2015to2020 AT patriceforget opioidandgabapentinoidprescriptionsinenglandfrom2015to2020 |